Stephanie Sutton was an assistant editor at Pharmaceutical Technology Europe.
The prevalence of substandard or counterfeit safety products and personal protective equipment (PPE) has become a "very serious" problem in the UK, according to the British Safety Industry Federation (BSIF), and could be putting workers in the pharma industry at risk.
A smart nanocage that can be filled with a medicinal substance and then activated using light has been developed by US researchers.
The engine of biopharmaceutical innovation is broken, according to Eli Lilly's Chairman and CEO, John C. Lechleiter.
A new pharmaceutical company with a focus on rare diseases has been formed in Sweden following the merger of the Swedish companies Biovitrum and Swedish Orphan.
The European Organisation for Rare Diseases (EURORDIS) has predicted that 100 new designated orphan products will receive marketing authorization between 2009 and 2019, which equates to approximately 10 new products every year.
The European Organization for Rare Diseases (EURORDIS) predicts that 100 new designated orphan products will receive marketing authorization between 2009 and 2019, which equates to approximately 10 new products every year.
According to a survey conducted by Pharmaceutical Technology Europe (PTE), almost 50% of you believe that cost is the biggest limiting factor to innovation in the pharmaceutical packaging industry.
Cargill has recently announced a number of innovations connected to its range of polyol excipients.
An inhaler mouthpiece that optimizes drug delivery to the lungs and reduces the amount of wasted medication has been developed by US researchers.
A complaint submitted to the Federal Trade Commission has referred to Pfizer's acquisition of Wyeth as "potentially monopolistic" and has urged the Commission to see that "the proposed merger is not in the public interest and is in conflict with a wide range of President Obama's objectives".
The global API market has expanded from $69 billion in 2004 to more than $90 billion in 2008 at an average yearly growth rate of 7.2%, according to a report from the Italian Chemical Pharmaceutical Association (CPA).
The global API market has expanded from $69 billion in 2004 to more than $90 billion in 2008, according to a report from the Italian Chemical Pharmaceutical Association (CPA); in particular, the report noted a rapid growth rate for generic APIs.
The European Fine Chemicals Group (EFCG) gave an update of some of its activities at a press conference held at CPhI Worldwide (Spain) last week, and revealed some disturbing facts regarding counterfeit APIs, which the group is particularly concerned about.
Cheaper generic pharmaceuticals, emboldened by US law and patent challenges, restrict novel future innovations.
US-based CRO, Health Decisions, hopes to raise the efficacy standards for complex studies and help companies get products to market faster by establishing an international network of CROs.
The European Fine Chemicals Group (EFCG) gave an update of some of its activities at a press conference held at CPhI Worldwide (Spain) last week, and revealed some disturbing facts regarding counterfeit APIs, which the group is particularly concerned about.
ISP Pharmaceuticals is embarking on a Drug Solubility Initiative to support pharma companies working with poorly soluble drug actives.
SAFC Pharma has completed a $12-million expansion to its contract manufacturing facility in Carlsbad (CA, USA), which will expand the company's services for its later phase and commercial clients.
A new drug delivery method developed by scientists could enable prescription drugs to be buried inside the body where drug release could be prompted by a biological trigger, such as a drop in blood sugar levels, or activated manually with a pulse of light.
The EC has been knocking on the doors of pharmaceutical companies to conduct surprise inspections; the agency will be looking specifically for signs of anticompetitive behaviour.
A long-term joint venture between GlaxoSmithKline (GSK) and China's Jiangsu Walvax Biotech Company hopes to develop and manufacture paediatric vaccines for use in China.
Almac's expansion plans in Northern Ireland (UK) could see the creation of more than 500 jobs during the next 5 years.
The EMEA intends to fully implement its Product Information Management (PIM) approach, an initiative designed to improve information management, into the centralized procedure within 2 years, according to a statement of intent from the agency.
Two vaccines manufactured by Novartis and GlaxoSmithKline (GSK) against influenza H1N1 have been recommended by the EMEA for marketing authorization.
A new report evaluating the biotech sector in new EU member states and candidate countries has described biotech developments as "uneven" because of contrasting economic strategies in different countries.
A new report evaluating the biotechnology sector in new European Union member states and candidate countries has described biotech developments as "uneven" because of contrasting economic strategies in different countries.
Despite the economic downturn, Spain's pharmaceutical industry continues to grow - particularly when it comes to biotechnology.
Vetter (Germany) is intending to open a technologically advanced customer services facility at the end of 2009 in Chicago (US).
Many UK pharmaceutical companies are turning to basic business skills training to help them emerge from the recession stronger than before.
The Gerresheimer Group is opening two new centres: an R&D center for medical plastic systems in the US and a new production center for pharmaceutical plastic packaging in Spain.
